Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
D
054670
vs
K
KOSPI 200
Over the past 12 months, Daehan New Pharm Co Ltd has underperformed KOSPI 200, delivering a return of -18% compared to KOSPI 200's +116% growth.
Stocks Performance
054670 vs KOSPI 200
Performance Gap
054670 vs KOSPI 200
Performance By Year
054670 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Daehan New Pharm Co Ltd
Glance View
Daehan New Pharm makes and sells pharmaceutical products in South Korea. Its business is centered on medicines and hospital-use products such as injectable drugs and other sterile formulations, which require careful manufacturing and quality control. It sells these products to hospitals, clinics, pharmacies, and healthcare distributors that need reliable supply for everyday patient care. The company earns money by selling its own drug products and, in some cases, by supplying medicines made for other customers. In this kind of business, the key value is not branding alone but the ability to produce safe, consistent pharmaceutical products that meet strict regulatory standards. That makes Daehan New Pharm part of the supply chain between drug development and patient treatment. Compared with companies that focus mainly on drug discovery, Daehan New Pharm is more of a manufacturing and supply business. Its role is to turn approved medicines into finished products that healthcare providers can actually use. For beginner investors, the main thing to understand is that its fortunes depend on pharmaceutical demand, manufacturing quality, and its ability to keep hospitals and distributors supplied with trusted products.